Results 281 to 290 of about 414,010 (359)

Modulation of the Toll-like Receptor Pathway in Ovine Endometria During Early Pregnancy. [PDF]

Animals (Basel)
Yu G, Song M, Wu C, Ma X, Zhang L, Yang L.   +5 more
europepmc   +1 more source

Mucosal‐Associated Invariant T Cells in Rheumatic Diseases

Arthritis &Rheumatology, EarlyView.
Mucosal‐associated invariant T (MAIT) cells are innate‐like T cells defined by their semi‐invariant T cell receptor and restriction by the major histocompatibility complex class I–related molecule (MR1). These cells are primarily activated by microbial‐derived metabolites presented by MR1 or by cytokines.
Manon Lesturgie‐Talarek, Virginie Gonzalez, Lucie Beaudoin, Noémie Sénot, Corinne Miceli‐Richard, Yannick Allanore, Agnès Lehuen, Jerôme Avouac   +7 more
wiley   +1 more source

Identification of novel amino acid variants in the Han Chinese population that impair toll-like receptor 4 signaling and confer hyporesponsiveness to lipopolysaccharide. [PDF]

Front Immunol
Zhou B, Lv Z, Zu R, Liu J, Yang Y, Zhou Z, Li Y.   +6 more
europepmc   +1 more source

Orchestration of Skin Pathology in Cutaneous Lupus Erythematosus by HLA Class I Down‐Regulated Senescent Epidermal Basal Cells

Arthritis &Rheumatology, EarlyView.
Objective This study investigates the role of senescent epidermal basal cells in cutaneous lupus erythematosus (CLE) pathogenesis using skin samples from patients with CLE and a mouse model of systemic lupus erythematosus (SLE). Methods Cellular senescence profiling used datasets from the NCBI GEO database and Accelerating Medicines Partnership (AMP ...
Sena Yamamoto, Yuki Saito, Tsukasa Sato, Seina Nakano, Dain Kasseki, Ayaka Nagao, Norihiro Miura, Kentaro Nagaoka, Arisa Kita, Maki Miyajima, Shogo Ijima, Koji Taniguchi, Atsushi Niida, Takako S. Chikenji   +13 more
wiley   +1 more source

Pharmacological inhibition of toll-like receptor 4 suppresses ischemia-reperfusion injury-induced inflammation and improves lung allograft function after transplantation. [PDF]

JHLT Open
Goda Y, Takahashi M, Yuasa I, Shimazu Y, Date N, Tanaka S, Katsuragawa H, Ohsumi A, Nakajima D, Date H.   +9 more
europepmc   +1 more source

Antiphospholipid Syndrome: An Antibody‐Mediated Disease With Emerging Therapeutic Opportunities

Arthritis &Rheumatology, EarlyView.
Antiphospholipid syndrome (APS) is an autoimmune thromboinflammatory disease characterized by vascular thrombosis, pregnancy morbidity, and other manifestations driven by antiphospholipid autoantibodies. In this review, we present a clinical case that illustrates some diagnostic and therapeutic challenges in managing severe, relapsing APS ...
Thalia G. Newman, Jason S. Knight
wiley   +1 more source

Toll-like Receptor 9 Mediates Epstein-Barr Virus-Aggravated Inflammation in a Mouse Model of Inflammatory Bowel Disease. [PDF]

Biomedicines
Nour Eddine HF, Kassem AM, Salhab Z, Sherri N, Moghabghab K, Mohsen Z, Naim G, Mahmoud S, Jurjus A, Hashash JG, Rahal EA.   +10 more
europepmc   +1 more source

Role of toll-like receptors in pulmonary immunity: mechanisms and therapeutic implications

Zhuojian Qu, Zhiliang Guo, Chunjuan Yang, Xiumei Guan, Min Cheng, Pingping Wang, Donghua Xu   +6 more
openalex   +1 more source

Pharmacodynamic Effects of Litifilimab in Lupus in a Randomized, Placebo‐Controlled Phase 2 Study: Rapid and Sustained Reductions in Type I Interferon‐Associated Gene Expression and Cytokines

Arthritis &Rheumatology, EarlyView.
Objective The pharmacodynamic effects of litifilimab on type I interferon (IFN) response and correlations with clinical outcomes were investigated in systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). Methods Participants from part A (SLE) or part B (CLE with or without SLE) of the randomized phase 2 LILAC trial who received ...
Richard Furie, Victoria P. Werth, Eric Milliman, Kyle Ferber, Roland Brown, Jad Zoghbi, Nathalie Franchimont, Youmna Lahoud, Catherine Barbey   +8 more
wiley   +1 more source

Corrigendum: Pharmacological Inhibition of Macrophage Toll-like Receptor 4/Nuclear Factor-kappa B Alleviates Rhabdomyolysis-induced Acute Kidney Injury

openalex   +1 more source